Assessing Risk Factors of Oral JAK Inhibitors and Traditional Agents

EP: 1.JAK Inhibitor Overview and Relevance to AD

EP: 2.Comparing Current Treatment Agents for AD

EP: 3.Clinical Experience With JAK Inhibitor in AD

EP: 4.Experts Present Background on Long-Term Safety Study of Upadacitinib for AD

EP: 5.Experts on Results of Long-Term Safety Study of Upadacitinib for AD

EP: 6.Conclusions of Study on Long-Term Safety Study of Upadacitinib for AD

Now Viewing

EP: 7.Assessing Risk Factors of Oral JAK Inhibitors and Traditional Agents

EP: 8.Experts Present Background on JAK Inhibitor vs Systemic Immunosuppressant Safety Study

EP: 9.Experts on Results of JAK Inhibitor vs Systemic Immunosuppressant Safety Study

EP: 10.Visualizing Safety Rates: Drug Events, Disease Baseline, and General Population Baseline

EP: 11.Box Warning and JAK Inhibitor

EP: 12.JAK Inhibitor Selectivity

EP: 13.Conclusions of JAK Inhibitor vs Systemic Immunosuppressant Safety Study

EP: 14.Evolving the Standard of Care for AD: Safety and Treatment Response

EP: 15.Transitioning Patients from Traditional Immunosuppressive Agents to JAK Inhibitor

EP: 16.AD Endotypes and Outcomes

EP: 17.Final Thoughts on JAK Inhibitor for AD

Christopher Bunick, MD, PhD: Ruth Ann, given this background on the safety of upadacitinib and JAK inhibitors as a whole, how does the safety speak to how you’re going to prescribe these medicines? Compare them with what we’ve traditionally used: immunosuppressive agents like steroids, cyclosporine or methotrexate.

Ruth Ann Vleugels, MD, MPH, MBA: That’s a great question. What you just went through made me think of an important point that I usually discuss with my colleagues when they ask me about my comfort level in prescribing JAK inhibitors. A really important point is that some of the concerns with JAK inhibitors came from the data from patients with rheumatoid arthritis [RA], who have an increased risk of clotting, cardiovascular risk factors, and malignancy at baseline. This makes it the study population different from the population we’re talking about in dermatology, like our patients with atopic dermatitis [AD].

A study that’s really important to think about is when they look at upadacitinib-treated patients with RA, the clotting and cardiovascular risk factors aren’t any higher than when those same patients with RA are treated with methotrexate or adalimumab or even RA at baseline. Similarly, when they follow those patients over time, there’s no increased risk. That’s crucial in thinking about how we consider using medications. We have to know the patient population well. Of course I’m going to think about these risk factors in my patients. Patient selection is important. But the data that are evolving show us that in our patients with AD, these medicines are ones that we can comfortably reach for as long as we select our patients appropriately. More importantly, I’d strongly prefer to avoid systemic steroids in repeated courses for any of my patients with AD. They’re not a long-term solution. Some of these problems we’re discussing in terms of clotting risk and cardiovascular outcomes are higher in patients on systemic steroids or cyclosporine than the medications we’re talking about today, which are also more efficacious. That’s an important point to think about when you’re counseling patients.

TRANSRIPT EDITED FOR CLARITY